Latest News
& Press Releases

Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease’s origin. Here are the latest updates on the monkeypox virus.

The FDA’s Vaccines and Related Biological Products Advisory Committee is set to review clinical data on June 7 and potentially suggest approval of NVX-CoV2373.

Four biotech companies are holding Research-and-Development Day events to present and discuss their pipelines. Here’s a look.

Researchers at the University of California, Los Angeles have identified a neurological mechanism behind memory linking.

The new R&D facility is a product of its new licensing deal with BridgeBio Pharma and will operate under Helsinn Therapeutics.

Shares of Enochian Biosciences plunged more than 36% after the Justice Department announced company cofounder Serhat Gumrukçu was arrested in a sordid 2018 murder-for-hire scheme.

A recent study published in Nature Medicine found that people who were vaccinated had a slightly decreased risk of getting Long COVID six months after their initial diagnosis.

Flagship Pioneering introduced ProFound Therapeutics, a new company that leverages previously undiscovered human proteins to develop treatments for many diseases.

Invectys is one of only a few companies investigating HLA-G, a natural immune checkpoint inhibitor, for solid tumors.

At the start of Takeda’s fiscal year on April 1, Ramona Sequeira and Julie Kim stepped into new positions on the company’s executive leadership team and became role models for women.

When the two new sites are up and running, Eli Lilly predicted the project will create up to 500 new jobs - with the expectation of four indirect jobs for each full-time position, based on industry data.

Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments